The short answer
ESSENCE is a Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis, registered as NCT04822181 with 1,205 participants. Sanyal and colleagues published results in the New England Journal of Medicine in June 2025.
Key facts
- Trial
- ESSENCE, NCT04822181
- Phase
- 3
- Enrolment
- 1,205
- Status
- Active, not recruiting
- Condition
- MASH (formerly NASH)
- Published
- NEJM 2025 (PMID 40305708)
- Design paper
- Newsome 2024 (PMID 39412509)
What MASH is
Metabolic dysfunction-associated steatohepatitis: fat accumulation in the liver accompanied by inflammation and liver cell injury, which can progress to fibrosis and cirrhosis. It was called NASH (non-alcoholic steatohepatitis) until a renaming that shifted the emphasis from what the condition is not to what drives it. The trial registration still carries the older name.
Why an incretin was an obvious candidate
MASH sits downstream of the same metabolic disturbance that produces obesity and type 2 diabetes. A drug that substantially reduces body weight and improves glycaemic control is acting on the upstream drivers, so the hypothesis is mechanistically coherent rather than opportunistic. Whether the benefit is weight reduction alone or something more direct is a separate and unsettled question.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why liver trials are unusually difficult
The endpoints require liver biopsy. Histological scoring of inflammation, ballooning and fibrosis is a pathologist's judgement, not a machine reading, and inter-observer variability is well documented. Trials therefore need central reading, and even then the endpoint is noisier than a blood pressure or an HbA1c. This is a substantial reason MASH drug development has been slow.
What the trial reports on
Resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis without worsening of steatohepatitis. These are the two histological endpoints this field has converged on. Both are surrogates for what actually matters, which is progression to cirrhosis, liver failure and death over timescales no trial can practically cover.
The regulatory consequence of that
Because the endpoints are surrogates, approvals in this area have come through accelerated pathways that require confirmatory evidence afterwards. That is a different kind of approval from one granted on clinical outcomes, and the distinction is rarely made in coverage.
What it does not concern
Research material. Semaglutide is a licensed medicine, ESSENCE is a registered trial conducted under clinical supervision, and nothing supplied here is semaglutide, related to it, or an alternative to any liver treatment.
Frequently asked questions
Why are liver trials so difficult?
The endpoints require biopsy and histological scoring, which is a pathologist's judgement with documented inter-observer variability.
Are the endpoints clinical outcomes?
No. They are histological surrogates for progression to cirrhosis and death, which no trial can practically follow to completion.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSanyal AJ et al., Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. NEJM 2025 (PMID 40305708)pubmed.ncbi.nlm.nih.gov
- PubMedNewsome PN et al., Semaglutide 2.4 mg in MASH: baseline characteristics and design of ESSENCE. Aliment Pharmacol Ther 2024 (PMID 39412509)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · ESSENCE (NCT04822181)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- FLOW: A Kidney Outcome Trial, Stopped Early3,533 participants with type 2 diabetes and chronic kidney disease. What FLOW measured, and why it is a harder kind of evidence than a weight trial.
- SELECT: The Trial That Changed What the Class Was For17,604 participants with obesity and cardiovascular disease but no diabetes. Why studying that population specifically was the point.
- The Attribution Problem Running Through Every IndicationHeart, kidney and liver benefits all appear alongside substantial weight reduction. Separating the two is harder than it looks, and mostly has not been done.
- Why Biopsy Endpoints Make Liver Trials HardMASH trials score liver biopsies for inflammation and fibrosis. A pathologist's judgement is a noisier endpoint than a number from a machine.
- STEP UP: Testing Whether More Dose Means More EffectA phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults. Why raising the dose is not a trivial question and what a ceiling would mean.